The concept was so tantalizing. Medication within the GLP-1 class, which incorporates Wegovy and Ozempic, have proved miraculous in treating weight reduction and different ailments. And a few researchers hoped that the medication may additionally assist with among the most troublesome ailments to deal with — these of the mind, like Parkinson’s.
However now, not less than for Parkinson’s, that hope appears dimmed. A rigorous examine that randomly assigned Parkinson’s sufferers to take exenatide, a relative of Ozempic, confirmed completely no profit or slowing of the course of the degenerative illness after 96 weeks.
And there have been no impact on affected person signs, no impact on mind scans, no subgroup that confirmed any profit. Irrespective of how the researchers sliced the info the outcomes have been the identical.
The examine, printed Tuesday in The Lancet, is unhealthy information for the half million People who’ve been recognized with Parkinson’s illness. Signs embody tremors, stiffness and problem with stability. Sufferers additionally could develop dementia. Remedies, together with drugs and deep mind stimulation, may help with signs. However no therapy has been proven to sluggish the illness’s progress.
“It’s vastly disappointing,” mentioned Dr. Thomas Foltynie of College School London, who led the trial. “We have been anticipating we’d come by and we’d get a constructive end result.”
Parkinson’s consultants shared his sentiment.
“This can be a sobering second,” mentioned Dr. Michael S. Okun, a Parkinson’s illness knowledgeable on the College of Florida and the nationwide medical adviser for the Parkinson’s Basis. “This can be a very well carried out examine and it got here up empty-handed.”
The discovering could have implications for researchers who’re asking if the newer GLP-1 medication may assist sluggish the course of Alzheimer’s or may stop the illness.
The brand new examine concerned 194 individuals with Parkinson’s illness handled at six analysis hospitals within the U.Ok. The sufferers have been randomly assigned to inject themselves as soon as per week for 96 weeks with exenatide, a sort 2 diabetes therapy made by AstraZeneca and bought beneath the model identify Byetta, or with a placebo. The trial was funded by Britain’s Nationwide Institute for Well being and Care Analysis with help for substudies from the charity Treatment Parkinson’s and the Van Andel Institute.
The drug is in the identical class as Ozempic and Wegovy and, like them, lowers blood sugar ranges. All are so-called GLP-1 receptor agonists, generally known as GLP-1s. Exenatide just isn’t as highly effective in eliciting weight reduction because the newer medication, however consultants say there isn’t a cause to imagine that the more moderen medication would carry out in another way in research of mind illness.
The outcomes, researchers mentioned, are particularly disappointing as a result of there have been recommendations that GLP-1 medication may assist Parkinson’s sufferers.
GLP-1 medication protected neurons from harm in laboratory research and in a examine with rats given a mind harm like that in Parkinson’s illness.
It started to look that the outcomes may additionally apply to sufferers.
“Individuals began digging into claims databases,” Dr. Okun mentioned, explaining that researchers had examined giant databases exhibiting medication that individuals took and their diagnoses. The researchers requested if sufferers who had taken GLP-1s may be much less prone to get Parkinson’s or, if they’d it, would have a illness that progressed extra slowly.
The outcomes have been promising.
They regarded at epidemiological research. They discovered that individuals with diabetes who took GLP-1s have been much less prone to have Parkinson’s.
Then two small research urged that exenatide may sluggish the development of some Parkinson’s signs over a yr’s time.
Persevering with the hints of progress, a bigger however nonetheless preliminary examine, printed final yr within the New England Journal of Medication, discovered {that a} GLP-1 that’s now not available on the market — lixisenatide — appeared to barely sluggish progress of the illness over a yr.
Dr. Okun, on the time, mentioned that the end result was “nibbling on the edges of illness modification.”
“What we had final yr was a one-year trial and a small sign,” mentioned Dr. David Standaert, a Parkinson’s researcher on the College of Alabama at Birmingham. “What would occur for those who went longer? Nicely, that is longer and there’s simply not a lot right here.”
The issue with finding out GLP-1s in Parkinson’s illness, Dr. Standaert mentioned, is that what exenatide is meant to be doing within the mind just isn’t clear.
“I wouldn’t do one other examine like this until you be taught what’s the goal,” Dr. Standaert mentioned. “What’s the biochemistry you are attempting to alter within the mind? How do these medication work, anyway?”